Abstract
Lungs remain one of the most difficult solid organs for xenotransplantation, owing to its delicate alveolar capillary barrier and intense crosstalk between innate immunity and coagulation system. Multi-gene-engineered donor pig organs combined with co-stimulation pathway blockade based immunosuppressive regimen have extended xenograft survival in preclinical models using non-human primates (NHP) from hours to weeks. Most recently, the first case of lung xenotransplantation into a brain-dead human recipient was reported, confirming technical feasibility without hyperacute rejection while revealing early inflammatory injury and progressive dysfunction. Key barriers include loss of vascular barrier function, dysregulated coagulation and platelet function driven by porcine-human molecular incompatibilities, and antibody-mediated injury. Preclinical data implicate innate immune activation such as natural killer cells and macrophages. Unlike kidney xenotransplantation, which has achieved stable long-term outcomes in NHPs, lungs require attention to immunogenicity against the “fourth antigen” in triple-knockout (TKO) donors that include the positive crossmatch created by the CMAH deletion when TKO organs are tested in NHP. Although consistent multi-month lung xenograft survival has not yet been achieved in preclinical models, the remaining barriers to clinical translation are being defined. This review delineates lung-specific xeno-immune mechanisms and advances aimed at their mitigation, providing insights necessary for future clinical translation.
Introduction
Lung transplantation is the gold standard and final therapeutic option for various types of end-stage chronic pulmonary diseases. However, the persistent global shortage of donor organs remains a critical challenge. Despite the utilization of expanded-criteria donors, including donation after circulatory death, and advancements in organ allocation systems, the waitlist mortality remains alarmingly high at over 28 deaths per 100 person-year [1]. Long waiting time and high waitlist mortality highlight the urgent need for alternative solutions. Xenotransplantation—the transplantation of organs from one species to another—has emerged as a promising alternative to address this unmet need. Recent milestones include pig‐to‐human heart [2] and kidney [3] xenotransplantation under “compassionate use” circumstances. These breakthroughs leveraged extended graft survival and function achieved in non-human primate (NHP) models using multi-genetically engineered (GE) pigs and advanced immunosuppressive regimens targeting co-stimulation pathway [4–6].
Lung xenotransplantation presents unique and formidable challenges due to the lung’s delicate alveolar architecture, large populations of resident immune cells, and inherent susceptibility to inflammation. Xeno lung differs from allo lung by triggering a host of innate immune injury mechanisms that do not normally play any significant role in allo, amplifying the deleterious consequences of inflammation and injury. Lung injury or inflammation typically leads to loss of vascular barrier function, alveolar flooding, and progressive loss of gas transfer functionality. Specifically, the immediate activation of pig lung macrophages after exposure to human blood, rapid accumulation of human neutrophils, and severe platelet sequestration and activation pose hurdles to achieving even short-term lung xenograft survival in NHP model or during ex vivo perfusion with human blood [7–10].
Despite multiple breakthroughs that have enabled improved preclinical results and even clinical translation of kidney and heart xenotransplantation, progress in the lung xenotransplantation has remained comparatively limited [11, 12]. Even with similar gene modifications and further intensified immunosuppressive protocols, preclinical NHP models of lung xenotransplantation (including a recent pig lung in a ‘decedent’ human) reported survival of only a few days to weeks [7, 13].
This review aims to provide a comprehensive overview of the current state of xeno-lung transplantation, highlighting recent scientific breakthroughs, ongoing challenges, and future directions. By synthesizing findings from preclinical studies and experimental models, this article seeks to inform future research and clinical translation efforts in this rapidly evolving field.
Structural Vulnerabilities and Immunological Barriers in Lung Xenografts
The extensive surface area of lung vascular endothelium represents a primary initial target of injury in xenogeneic lung transplantation. This endothelium, intimately associated with the alveolar epithelium via a thin connective tissue layer and basement membrane, is a principal target for preformed anti-pig antibodies, “recipient” innate immune cells such as neutrophils, NK cells, and monocytes, and coagulation pathway component adhesion and activation [11]. The lungs also harbor a specialized immune surveillance network, comprised of tissue-resident macrophages, basophils, eosinophils, and other inflammatory cells that normally participate in lung tissue surveillance. While this system is highly effective in detecting and responding to pathogens, it renders the lungs uniquely susceptible to local inflammatory reactions compared with other transplanted organs. Endothelial activation and injury results in loss of vascular barrier function with alveolar flooding which prevents gas exchange in that lung region, exacerbating graft failure [14, 15]. Our prior research consistently demonstrates that inflammatory responses in both the xenograft and the recipient are significantly more pronounced for lung xenografts compared to other pig organs [5, 11, 16–27].
The intrinsic vulnerability of the lungs to xenogeneic injury arises from the interplay of innate immune pathways and interspecies physiological mismatches. Preformed antibodies, particularly those directed against the α-1,3-galactose (α-Gal) epitope, rapidly bind to donor endothelial cells, triggering complement activation and hyperacute rejection within minutes [28, 29]. This cascade leads to endothelial damage, microvascular thrombosis, and pulmonary edema, culminating in graft failure. While the genetic knockout of the galactosyltransferase enzyme (GalTKO) has effectively eliminated α-Gal-mediated hyperacute rejection in other organs [30, 31], subsequent studies revealed that innate and adaptive immune responses persist [18, 32–35]. These responses target other porcine antigens, including those derived from the N-Glycolylneuraminic acid (Neu5Gc/CMAH) and β-1,4-N-acetyl-galactosaminyltransferase 2 (β4Gal) genes [36]. Lungs from GalTKO.CMAHKO.human CD46 (hCD46) pigs, when perfused ex vivo with human blood, showed significant reductions in thrombin generation, thromboxane and histamine release, and pulmonary vascular resistance compared to controls without CMAHKO [37]. This genetic combination delays the onset of pulmonary vascular injury and preserves graft function [37].
Building on these findings, triple-knockout (TKO) pigs (GalTKO.CMAHKO.β4GalKO) have shown further improvements. In a notable in vivo experiment, lungs from these genetically engineered pigs supported baboon recipients for 5 days without the need for additional human protective transgenes [7]. In comparison, GalTKO lungs without CMAHKO or β4GalKO typically fail within 24 h and provide only marginal function [7]. While the TKO approach initially appeared to be the optimal and foundational genetic modification for xenotransplantation, subsequent research has revealed a new challenge.
Baboons and other Old World NHP possess antibodies against TKO pig cells, apparently targeting a “fourth xenoantigen” that becomes exposed following CMAHKO [38–40]. Our pilot data also support this finding: in vivo experiments using genetically engineered pig with 10 genetic modifications (10GE) (TKO. Growth hormone receptor knockout [GHKO].hCD46.hCD55.human endothelial protein C receptor [hEPCR].human thrombomodulin [hTBM].human heme oxygenase-1 [hHO-1].hCD47) pig lungs elicited high levels of innate immune system activation and systemic inflammation in baboon recipients (unpublished). In contrast, the longest survival observed in our in vivo studies (31 days) was achieved using pig lungs from donors with “double knockout” (DKO) (GalTKO.β4GalKO) [7]. These findings suggest that TKO organs—even in the widely used 10GE construct or in pigs with fewer genetic modifications—are insufficiently protected against immune-mediated injury in NHP models. However, the positive cross-matches against GalTKO + CMAHKO or TKO cells were not observed in human [39, 41].
We believe this phenomenon undermines the predictive accuracy of NHP-based transplant results for clinical outcomes, as these immune challenges are unlikely to occur in human recipients. Consequently, while NHP studies provide valuable insights, their results may underperform in reflecting the true potential of these genetically modified organs in clinical settings, emphasizing the importance of refining genetic constructs and preclinical models including work in human ‘decedents’. In August 2025, a Chinese group reported the first experimental single left lung xenotransplantation into a brain-dead ‘decedent’ human patient, observing the organ’s histologic appearance for a 9-day period. By day 1 the posterior >80% of the lung xenograft appeared to be filled with fluid, suggesting rapid loss of barrier function, similar to pig-to-baboon lungs when well-described lung xeno rejection mechanisms are not inhibited. This model, if additionally used to assess life-supporting lung function, offers the potential to yield valuable insights into the current viability of and remaining challenges for clinical lung xeno application [13].
Inflammatory and Thrombotic Pathways in Lung Xenotransplantation
The sequestration and activation of circulating leukocytes and platelets are hallmark features of lung xenograft injury, uniquely severe compared to other xenografted organs. These processes persist even when antibody binding and complement activation are minimized, indicating that additional adhesive and activation mechanisms play significant roles in the pathogenesis [11]. Porcine endothelial cells are potent activators of human leukocytes, primarily through cytokine elaboration and species-specific incompatibilities in cellular pathways.
Interleukin-8 (IL-8), a key chemoattractant produced by porcine endothelial cells, significantly promotes neutrophil adhesion and rolling on the endothelium [42]. Elevated IL-8 levels observed in ex vivo pig lung perfusion models stimulate human neutrophil activation and adhesion, exacerbating pulmonary vascular resistance (PVR) and vascular barrier dysfunction [42]. Additionally, porcine endothelial selectins, such as P- and E-selectin, enhance neutrophil tethering and rolling, further amplifying leukocyte infiltration [43]. Blocking these selectin-mediated interactions with inhibitors like GM1271 (E-selectin) and rPSGL-1 (P-selectin) has shown efficacy in mitigating neutrophil-mediated damage [43].
Platelet activation plays a similarly critical role in lung xenograft injury. Porcine von Willebrand factor (pvWF), expressed and released by porcine endothelial cells, demonstrates abnormal interactions with human glycoprotein Ib (GPIb). Unlike human von Willebrand factor (hvWF), which binds weakly to GPIb under normal conditions and requires high shear stress for activation, pvWF activates quiescent human platelets even under low shear stress. This aberrant interaction leads to pathological platelet aggregation and microvascular thrombosis, significantly contributing to the prothrombotic environment within the xenograft. Such conditions exacerbate vascular occlusion and graft injury, creating a formidable barrier to long-term lung xenograft survival [44].
Donor lung pretreatment with desmopressin (DDAVP), as reported by a Korean group, reduces platelet activation by depleting pvWF from endothelial cells and minimizing its interaction with GPIb [45]. Our ex vivo lung perfusion studies further support this approach, demonstrating that pre-depletion of pvWF using DDAVP, combined with the administration of GPIb antagonists, effectively attenuates platelet activation [20]. Moreover, humanizing pvWF by replacing a portion of the gene region encoding the GPIb-binding site with its human analogue in GalTKO.hCD46 pig lungs has been shown to suppress non-physiological human platelet aggregation and sequestration within the pig lung and liver [46]. This genetic modification represents a pivotal advancement, providing a safer and more effective approach to lung xenotransplantation. Importantly, it may also facilitate xenotransplantation applications for other organs and cells, broadening its potential clinical impact.
Coagulation Cascade Activation and Dysfunctional Thromboregulatory Mechanisms
Coagulation abnormalities are a major contributor to lung xenograft injury, driven by endothelial cell activation or damage, which triggers the coagulation cascade and leads to rapid thrombus formation. Key factors implicated in this process include TBM, EPCR, and TFPI. Although porcine TBM can bind human thrombin to form a thrombomodulin-thrombin complex, its protein C activation efficiency is only 1%–10% that of hTBM [47, 48]. Similarly, porcine EPCR and TFPI, which inhibit extrinsic coagulation pathway factors, exhibit significantly reduced activity compared to their human counterparts [47, 49–52].
Our ex vivo perfusion model using human blood demonstrated that expressing hTFPI in GalTKO pig lungs effectively suppressed neutrophil activation and provided protective effects, supporting the hypothesis that human-derived coagulation regulatory factors are critical for mitigating graft injury [10]. Baboon in vivo models further revealed that co-expression of hEPCR and hTBM was associated with reduced β-thromboglobulin (βTG) levels, consistent lung survival beyond 12 h, and a higher rate of achieving initial life-supporting xenograft function [7]. However, these advances can only delay the onset of barrier dysfunction and fail to completely prevent it.
Early production of thromboxane and histamine also contributes to loss of barrier function [19]. Treatment with the selective thromboxane inhibitor 1-benzylimidazole (1-BIA) combined with H-2 or non-selective histamine receptor antagonists significantly suppressed PVR elevation and delayed vascular barrier dysfunction [21]. However, the combination of drug regimens targeting inflammatory cytokines such as tumor necrosis factor-α (TNF-α), IL-8, and IL-6 have not fully eliminated these mediators, and barrier dysfunction persists. These findings highlight the need for further investigation into the mechanisms driving coagulation abnormalities and inflammation to develop more effective therapeutic strategies.
Complement-Mediated Lung Xenograft Injury
Complement activation is particularly pronounced in lung xenotransplantation due to the organ’s high vascular density and unique susceptibility to immune-mediated injury. To prevent some protection against activation of the complement pathway, human complement regulatory proteins (CPRPs)—including decay accelerating factor (DAF_CD55), membrane cofactor protein (MCP_CD46), and membrane-attack-complex-inhibitory protein (MAC-IP_CD59)—have been introduced into the organ source pigs [53]. (Porcine CPRPs are not very effective at controlling human complement activation due to interspecies molecular incompatibilities and differences in their expression levels on vascular endothelium [54, 55]).
In addition, several pharmacological approaches have been explored to mitigate complement activation in lung xenografts, including the use of C1-esterase inhibitor, soluble complement receptor 1 (sCR1), FUT-175, and depleting agents such as cobra venom factor (CoVF). While these strategies have demonstrated partial success, none has provided a definitive solution [56–58]. To address this challenge, genetic introduction of human complement regulatory proteins (hCPRPs), such as CD46, CD55, and CD59, has been investigated. When combined with DKO or TKO backgrounds, these genetic modifications have shown promising results in preclinical in vivo models. Specifically, hCPRPs expression in xenografts has been associated with reduced complement deposition, decreased platelet activation, and delayed graft injury in lungs, as well as in other organs such as the heart and kidneys [19, 59, 60].
Self-Recognition and Xenograft Injury by Macrophage and Natural Killer Cell
Cellular immune mechanisms are central to lung xenograft injury, involving macrophages and natural killer (NK) cells. Signal regulatory protein alpha (SIRPα), a key inhibitory receptor expressed on macrophages, plays a crucial role in distinguishing self from non-self. Interaction between SIRPα and its ligand, CD47 prevents autologous phagocytosis [61, 62]. However, in the absence of this interaction, porcine cells become highly susceptible to phagocytosis by human macrophages. Introducing human CD47 into porcine cells significantly reduces this susceptibility and effectively inhibits macrophage-mediated phagocytosis [63, 64]. Yamada et al. further reported that expressing CD47 in porcine lungs extended chimerism after bone marrow transplant and improved xeno-lung recipient survival in baboons [65]. While Watanabe et al. reported up to 10-day survival in baboon recipients using a GalTKO base with hCD47 expression alone, our series using GalTKO.hCD46 backgrounds with hCD47 alone or in combination with other humanized proteins (e.g., hEPCR, hTBM, hCD55, human tissue factor pathway inhibitor [hTFPI], and HO-1) failed to achieve consistent survival beyond 2 days [7]. Anatomical localization of hCD47 within the graft may influence its efficacy, warranting further investigation [66].
Pre-harvest donor macrophage depletion using liposomal clodronate has shown attenuation of acute ischemia reperfusion injury in a mouse lung allotransplant model and prevented endotoxin-induced acute lung injury in pigs showing significantly lower levels of TNF-α, IL-6, and thrombin [67, 68]. When it is applied to xenotransplantation, macrophage depletion significantly attenuates hyperacute rejection in wild-type pigs [22, 69]. In our in vivo baboon model, not only the use of liposomal clodronate but also anti-pig antibody absorption and cytokine inhibition were associated with longer xeno-lung recipient survival [7].
In addition to CD47, human CD39 and CD73 have emerged as promising anti-inflammatory mediators. These molecules convert extracellular pro-inflammatory ATP into AMP, reducing inflammation and vascular constriction [70, 71]. Genetically engineering porcine lungs to express human CD39 and CD73 could further suppress inflammation and enhance graft survival by modulating the graft’s immune microenvironment.
Natural killer (NK) cells play a dual role in xenograft injury by identifying and lysing non-self cells through both antibody-dependent and independent mechanisms. A critical factor driving NK cell activation in xenografts is the incompatibility between human inhibitory receptors and the porcine major histocompatibility complex (MHC), also known as swine leukocyte antigens (SLA). This weak interaction fails to deliver the necessary inhibitory signals, leaving porcine cells vulnerable to NK cell-mediated destruction [72]. Moreover, the absence of human leukocyte antigen E (HLA-E) on porcine endothelial cells exacerbates NK cell activation by preventing the recognition of negative regulatory signals [73, 74]. In contrast, lungs from GalTKO.hCD46 pigs expressing HLA-E demonstrated substantial protection against NK cell attacks both in vitro and in an in vivo model, leading to reduced early graft injury and prolonged survival in preclinical models [74–76].
Immunosuppressive Regimen and Targeted Drug Therapies
Optimal immunosuppressive regimens for lung xenotransplantation remain undefined. Building on the promising outcomes of co-stimulation pathway blockade in cardiac and renal allo- and xenotransplantation [2, 5, 77–81], strategies targeting CD154/CD40 and CD28/B7 pathways have been investigated in vivo lung xenograft models [7]. While these approaches have shown potential in modulating adaptive anti-xeno immunity, they are insufficient as standalone therapies. Consequently, co-stimulation blockade has been combined with conventional immunosuppressive therapies commonly used in human organ transplantation, including pre-transplant induction with antithymocyte globulin (ATG) and anti-CD20 (rituximab), along with maintenance regimens comprising steroids and mycophenolate mofetil (MMF). Additionally, splenectomy is often performed in our in vivo models to reduce the reservoir of recipient B-cells available to generate de novo anti-pig antibodies as well as spleen-resident plasma cells responsible for elaboration of preformed ‘innate’ anti-pig antibodies, thus hoping to enhance immunosuppressive regimen efficacy [7].
To address the unique inflammatory mediators that we have observed to be elaborated in association with lung xenografts, various anti-inflammatory agents have been explored. We now consistently include anti-TNF-alpha (etanercept), anti-IL-8 (reparixin), anti-IL-6 receptor (tocilizumab), C1-esterase inhibitors, and alpha1-proteinase inhibitors based on the profile of cytokines we have measured in earlier work. Of note, consistent incorporation of all 4 of these reagents is not by itself sufficient to achieve consistent improvement in xenograft survival or prevention of initial barrier dysfunction [7].
A significant milestone in the field was reported in August 2025, when researchers in China conducted the first lung xenotransplantation in a brain-dead human recipient using a 6GE pig lung (TKO.CD55.CD46.TBM) [13]. The immunosuppressive regimen included induction with ATG and a tacrolimus-based protocol, supplemented with MMF, steroids, anti-IL-2 receptor (basiliximab), anti-C5 (eculizumab), Janus kinase (JAK) inhibitor (tofacitinib), and anti-CD80/86 (belatacept). Within the first 24 h radiologic imaging revealed consolidation of the majority of the lung xenograft. We suspect that resident pig lung macrophage activation triggered histamine and thromboxane elaboration, contributing to significant edema and alveolar damage. In addition, neutrophils, NK cells, and monocytes likely infiltrated the lungs and caused additional inflammation. While deposition of immunoglobulins suggesting antibody-mediated rejection (AMR) was not clearly observed until day 3 we suspect antibody deposition and complement activation were likely present earlier. The authors suggest that there were signs of improvement in parenchymal damage by day 9, but evidence to support this interpretation we do not find compelling. Although this is a single case report, it highlights two critical priorities for advancing lung xenotransplantation: it is essential to measure lung function in addition to histology in order to accurately predict likely performance of a pig lung xenograft implanted with therapeutic intent; and controlling severe inflammation, including AMR, during the first week post-transplant was not accomplished by the regimen this team tested.
In contrast to lungs, in vivo baboon models of cardiac and renal xenotransplantation have demonstrated prolonged graft survival with less intensive immunosuppressive and anti-inflammatory regimens [5, 76–81]. Elucidating the unique vulnerability of lung xenografts to inflammation and rejection by tailoring specific therapies to address them will be pivotal in advancing lung xenotransplantation toward clinical application. In Table 1 we summarize our view of the remaining major barriers, the strategies we have tested to date, and next steps as we have prioritized them, which we hope will allow us to accomplish consistent long-term lung xenograft survival in our preclinical model and, eventually, in humans.
TABLE 1
| Key issue | Key issue | Mitigation strategies deployed to date (genetic/pharmacologic) | Address gaps with next steps |
|---|---|---|---|
| Loss of vascular endothelial barrier function reflects the integrated consequence of these processes | Adaptive immune responses | ||
| Elicited cellular and humoral immunity against pig antigens | Safe, effective immunosuppressive regimen based on co-stimulation-blockade-based regimen | Verify anti-CD154 levels, test higher doses and additional drug combinations so as to prevent elicited anti-donor antibodies and optimize maintenance immunosuppression | |
| Innate immune responses | |||
| Dysregulated coagulation | hTBM/hEPCR/TFPI Thromboxane synthesis inhibitor |
Optimize endothelial gene expression levels, evaluate different gene combinations alone and with goal-directed anticoagulation therapy | |
| Platelet activation and sequestration | Donor vWF depletion with desmopressin Humanized vWF; GPIb blockade |
Incorporate humanized vWF into existing multi-GE pig lines Optimize anti-GPIb fab dosing |
|
| Complement activation | hCD46, hCD55, hCD59 and other human transgenes; complement depletion with cobra venom factor transitioning to C1 esterase inhibitor, C3 or C5 inhibitors | Optimize pharmacologic drug dosing algorithms, evaluate C3 and C4 inhibitors Evaluate different combinations of human complement regulatory transgenes at optimized expression levels in donor pig lungs |
|
| Injury mediated by preformed antibody | Carbohydrate xenoantigen deletion: α-Gal/β4GalNT2/CMAH Adsorption of preformed antibody by donor kidney perfusion B-cell depletion with rituximab; splenectomy |
Standardize crossmatch gating and non-Gal antibody profiling Evaluate CMAH-intact double-knockout (GalTKO.β4GalKO) lungs with 6 or more human transgenes targeting complement, coagulation, inflammation Plasma cell depletion or inhibition |
|
| Cytokine elaboration | Blockade of IL-6R, IL-8R, TNF-α α1 -proteinase inhibitor |
Test IL-1R, IL-33 antagonists as add-on to inhibit cytokine elaboration or block effects Explore cytokine absorption using blood filters |
|
| NK cells | HLA-E transgene to engage human CD94/NKG2A inhibitory signaling | Verify NK functional readouts (degranulation, cytotoxicity) in EVLP/NHP, and molecular evaluation of lung xenografts Evaluate CD38 depletion |
|
| Pulmonary macrophages | hCD47; donor macrophage depletion with liposomal clodronate | Develop strategies to inhibit recipient monocyte/macrophage influx, activation Add human-compatible SIRPα, hCD73 to pig edits |
|
| Neutrophils | Blockade of P/E-selectin/PSGL-1 and Mac-1 (CD11b/CD18) | Validate drug engagement, efficacy to inhibit targeted pathway; develop strategies to inhibit NETs Explore adding hCD200 to pig edits |
|
Known barriers to durable lung xenograft function, mitigation strategies tested to date, and planned next steps.
Abbreviations: β4GalNT2: β-1,4-N-acetyl-galactosaminyltransferase-2; CMAH: cytidine monophosphate-N-acetylneuraminic acid hydroxylase (Neu5Gc); EVLP: ex vivo lung perfusion; GPIb: glycoprotein Ib; hCD46/hCD47/hCD200: human cluster of differentiation 46, 47, 200; hEPCR: human endothelial protein C receptor; hTBM: human thrombomodulin transgenes; HLA-E: human leukocyte antigen-E; IL: interleukin; KO: knockout; Mac-1: integrin αMβ2; NETs: neutrophil extracellular traps; NK: natural killer; NHP: non-human primate; PSGL-1: P-selectin glycoprotein ligand-1; SIRPα: signal regulatory protein-α; TNF- α: tumor necrosis factor- α; TFPI: tissue factor pathway inhibitor; vWF: von Willebrand factor.
Conclusion
Multi-gene engineering of donor pig and mechanism-based adjuncts have extended experimental lung xenograft survival from hours to days and, in selected NHP models, to weeks of recipient survival. The first pig-to-human lung xenotransplantation in a brain-dead recipient confirmed technical feasibility without hyperacute rejection but underscored persistent lung-specific barriers, notably early vascular-barrier failure, coagulation and platelet dysregulation, and antibody-mediated injury. Evidence from preclinical studies also indicates roles for NK cells and for macrophages in acute injury pathways. Progress toward clinical exploration will need further improvement of outcomes in preclinical models. In addition to evaluation of TKO-based multi-GE pig lungs in decedents, we anticipate that results with DKO (GalTKO.b4GalKO.CMAH-intact) multi-GE pig genotypes in NHP models will better predict clinical performance of lung (and other organ) xenografts. Working in parallel in NHP and decedent models, we hope to facilitate identification of gene and drug combinations that are necessary and sufficient to effectively address and dependably overcome species-specific lung xeno barriers.
Statements
Author contributions
LB conceived the topic of the manuscript and ST wrote the first draft. LB and RP revised the manuscript. LB and RP read and approved the final version of the manuscript. All authors contributed to the article and approved the submitted version.
Funding
The author(s) declared that financial support was received for this work and/or its publication. Work in the authors’ laboratories is funded in part by NIH (through AI191384, AI153612), AI090959, AI146248, and S10 OD034375, and by sponsored research agreements with Revivicor, eGenesis, and Tonix.
Conflict of interest
LB is an employee of Revivicor, a subsidiary of United Therapeutics, a PBC.
The remaining author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
References
1.
Christie JD Van Raemdonck D Fisher AJ . Lung Transplantation. N Engl J Med (2024) 391(19):1822–36. 10.1056/NEJMra2401039
2.
Griffith BP Goerlich CE Singh AK Rothblatt M Lau CL Shah A et al Genetically Modified Porcine-to-Human Cardiac Xenotransplantation. N Engl J Med (2022) 387(1):35–44. 10.1056/NEJMoa2201422
3.
Kawai T Williams WW Elias N Fishman JA Crisalli K Longchamp A et al Xenotransplantation of a Porcine Kidney for End-Stage Kidney Disease. N Engl J Med (2025) 392(19):1933–40. 10.1056/NEJMoa2412747
4.
Anand RP Layer JV Heja D Hirose T Lassiter G Firl DJ et al Design and Testing of a Humanized Porcine Donor for Xenotransplantation. Nature (2023) 622(7982):393–401. 10.1038/s41586-023-06594-4
5.
Längin M Mayr T Reichart B Michel S Buchholz S Guethoff S et al Consistent Success in Life-Supporting Porcine Cardiac Xenotransplantation. Nature (2018) 564(7736):430–3. 10.1038/s41586-018-0765-z
6.
Reichart B Cooper DKC Längin M Tönjes RR Pierson RN III Wolf E . Cardiac Xenotransplantation: From Concept to Clinic. Cardiovasc Res (2023) 118(18):3499–516. 10.1093/cvr/cvac180
7.
Burdorf L Laird CT Harris DG Connolly MR Habibabady Z Redding E et al Pig-To-Baboon Lung Xenotransplantation: Extended Survival With Targeted Genetic Modifications and Pharmacologic Treatments. Am J Transpl (2022) 22(1):28–45. 10.1111/ajt.16809
8.
Chaban R McGrath G Habibabady Z Rosales I Burdorf L Ayares DL et al Increased Human Complement Pathway Regulatory Protein Gene Dose Is Associated with Increased Endothelial Expression and Prolonged Survival During Ex‐Vivo Perfusion of GTKO Pig Lungs with Human Blood. Xenotransplantation (2023) 30(4):e12812. 10.1111/xen.12812
9.
Burdorf L Gao Z Riner A Sievert E Harris DG Kuravi KV et al Expression of Human Thrombomodulin by GalTKO.hCD46 Pigs Modulates Coagulation Cascade Activation by Endothelial Cells and During Ex Vivo Lung Perfusion with Human Blood. Xenotransplantation (2023) 30(6):e12828. 10.1111/xen.12828
10.
Miura S Habibabady ZA Pollok F Connolly M Pratts S Dandro A et al Effects of Human TFPI and CD47 Expression and Selectin and Integrin Inhibition During GalTKO.hCD46 Pig Lung Perfusion With Human Blood. Xenotransplantation (2022) 29(2):e12725. 10.1111/xen.12725
11.
Burdorf L Azimzadeh AM Pierson RN III . Progress and Challenges in Lung Xenotransplantation: An Update. Curr Opin Organ Transpl (2018) 23(6):621–7. 10.1097/MOT.0000000000000582
12.
Chaban R Cooper DKC Pierson RN III . Pig Heart and Lung Xenotransplantation: Present Status. J Heart Lung Transpl (2022) 41(8):1014–22. 10.1016/j.healun.2022.04.010
13.
He J Shi J Yang C Peng G Ju C Zhao Y et al Pig-To-Human Lung Xenotransplantation into a Brain-Dead Recipient. Nat Med (2025) 31:3388–93. 10.1038/s41591-025-03861-x
14.
Den HWA Gielis JF Lin JY Van Schil PE De Windt LJ Moens AL . Lung ischemia-reperfusion Injury: A Molecular and Clinical View on a Complex Pathophysiological Process. Am J Physiol Heart Circ Physiol (2010) 299(5):H1283–99. 10.1152/ajpheart.00251.2010
15.
Ranieri VM Suter PM Tortorella C De Tullio R Dayer JM Brienza A et al Effect of Mechanical Ventilation on Inflammatory Mediators in Patients With Acute Respiratory Distress Syndrome. JAMA (1999) 282(1):54–61. 10.1001/jama.282.1.54
16.
Kim SC Mathews DV Breeden CP Higginbotham LB Ladowski J Martens G et al Long-Term Survival of Pig-To-Rhesus Macaque Renal Xenografts Is Dependent on CD4 T Cell Depletion. Am J Transpl (2019) 19(8):2174–85. 10.1111/ajt.15329
17.
Nguyen BNH Azimzadeh AM Zhang T Wu G Schuurman HJ Shuurman HJ et al Life-Supporting Function of Genetically Modified Swine Lungs in Baboons. J Thorac Cardiovasc Surg (2007) 133(5):1354–63. 10.1016/j.jtcvs.2006.11.043
18.
Nguyen BNH Azimzadeh AM Schroeder C Buddensick T Zhang T Laaris A et al Absence of Gal Epitope Prolongs Survival of Swine Lungs in an Ex Vivo Model of Hyperacute Rejection. Xenotransplantation (2011) 18(2):94–107. 10.1111/j.1399-3089.2011.00633.x
19.
Burdorf L Stoddard T Zhang T Rybak E Riner A Avon C et al Expression of Human CD46 Modulates Inflammation Associated With Galtko Lung Xenograft Injury. Am J Transpl (2014) 14(5):1084–95. 10.1111/ajt.12673
20.
Burdorf L Riner A Rybak E Salles II De Meyer SF Shah A et al Platelet Sequestration and Activation During GalTKO.hCD46 Pig Lung Perfusion by Human Blood Is Primarily Mediated by Gpib, GPIIb/IIIa, and Von Willebrand Factor. Xenotransplantation (2016) 23(3):222–36. 10.1111/xen.12236
21.
Burdorf L Harris D Dahi S Laird C Zhang T Ali F et al Thromboxane and Histamine Mediate PVR Elevation During Xenogeneic Pig Lung Perfusion with Human Blood. Xenotransplantation (2019) 26(2):e12458. 10.1111/xen.12458
22.
Collins BJ Blum MG Parker RE Chang AC Blair KS Zorn GL et al Thromboxane Mediates Pulmonary Hypertension and Lung Inflammation During Hyperacute Lung Rejection. J Appl Physiol (2001) 90(6):2257–68. 10.1152/jappl.2001.90.6.2257
23.
Ezzelarab MB Ekser B Azimzadeh A Lin CC Zhao Y Rodriguez R et al Systemic Inflammation in Xenograft Recipients Precedes Activation of Coagulation. Xenotransplantation (2015) 22(1):32–47. 10.1111/xen.12133
24.
Iwase H Ekser B Zhou H Liu H Satyananda V Humar R et al Further Evidence for Sustained Systemic Inflammation in Xenograft Recipients (SIXR). Xenotransplantation (2015) 22(5):399–405. 10.1111/xen.12182
25.
Iwase H Liu H Li T Zhang Z Gao B Hara H et al Therapeutic Regulation of Systemic Inflammation in Xenograft Recipients. Xenotransplantation (2017) 24(2):e12296. 10.1111/xen.12296
26.
Gao H Zhang Q Chen J Cooper DKC Hara H Chen P et al Porcine IL-6, IL-1β, and TNF-α Regulate the Expression of Pro-Inflammatory-Related Genes and Tissue Factor in Human Umbilical Vein Endothelial Cells. Xenotransplantation (2018) 25(5):e12408. 10.1111/xen.12408
27.
Zhang G Iwase H Wang L Yamamoto T Jagdale A Ayares D et al Is interleukin-6 Receptor Blockade (Tocilizumab) Beneficial or Detrimental to Pig-To-Baboon Organ Xenotransplantation? Am J Transpl (2020) 20(4):999–1013. 10.1111/ajt.15712
28.
Pierson RN III . Antibody-Mediated Xenograft Injury: Mechanisms and Protective Strategies. Transpl Immunol (2009) 21(2):65–9. 10.1016/j.trim.2009.03.008
29.
Lexer G Cooper DK Rose AG Wicomb WN Rees J Keraan M et al Hyperacute Rejection in a Discordant (Pig to Baboon) cardiac Xenograft Model. J Heart Transpl (1986) 5(6):411–8.
30.
Kuwaki K Tseng YL Dor FJMF Shimizu A Houser SL Sanderson TM et al Heart Transplantation in Baboons Using α1,3-Galactosyltransferase Gene-Knockout Pigs as Donors: Initial Experience. Nat Med (2005) 11(1):29–31. 10.1038/nm1171
31.
Yamada K Yazawa K Shimizu A Iwanaga T Hisashi Y Nuhn M et al Marked Prolongation of Porcine Renal Xenograft Survival in Baboons Through the Use of α1,3-Galactosyltransferase Gene-Knockout Donors and the Cotransplantation of Vascularized Thymic Tissue. Nat Med (2005) 11(1):32–4. 10.1038/nm1172
32.
Gonzalez-Stawinski GV Daggett CW Lau CL Karoor S Love SD Logan JS et al Non-Anti-Gal Alpha1-3Gal Antibody Mechanisms Are Sufficient to Cause Hyperacute Lung Dysfunction in Pulmonary Xenotransplantation. J Am Coll Surg (2002) 194(6):765–73. 10.1016/s1072-7515(02)01162-6
33.
Chen G Qian H Starzl T Sun H Garcia B Wang X et al Acute Rejection Is Associated with Antibodies to Non-Gal Antigens in Baboons Using Gal-Knockout Pig Kidneys. Nat Med (2005) 11(12):1295–8. 10.1038/nm1330
34.
Byrne GW Stalboerger PG Davila E Heppelmann CJ Gazi MH McGregor HCJ et al Proteomic Identification of Non-gal Antibody Targets After Pig-To-Primate Cardiac Xenotransplantation. Xenotransplantation (2008) 15(4):268–76. 10.1111/j.1399-3089.2008.00480.x
35.
Byrne GW Stalboerger PG Du Z Davis TR McGregor CGA . Identification of New Carbohydrate and Membrane Protein Antigens in Cardiac Xenotransplantation. Transplantation (2011) 91(3):287–92. 10.1097/TP.0b013e318203c27d
36.
Zhu A Hurst R . Anti‐N‐Glycolylneuraminic Acid Antibodies Identified in Healthy Human Serum. Xenotransplantation (2002) 9(6):376–81. 10.1034/j.1399-3089.2002.02138.x
37.
Chaban R Habibabady Z Hassanein W Connolly MR Burdorf L Redding E et al Knock‐Out of N‐Glycolylneuraminic Acid Attenuates Antibody‐Mediated Rejection in Xenogenically Perfused Porcine Lungs. Xenotransplantation (2022) 29(6):e12784. 10.1111/xen.12784
38.
Estrada JL Martens G Li P Adams A Newell KA Ford ML et al Evaluation of Human and Non-Human Primate Antibody Binding to Pig Cells Lacking GGTA1/CMAH/β4GalNT2 Genes. Xenotransplantation (2015) 22(3):194–202. 10.1111/xen.12161
39.
Yamamoto T Iwase H Patel D Jagdale A Ayares D Anderson D et al Old World Monkeys Are Less Than Ideal Transplantation Models for Testing Pig Organs Lacking Three Carbohydrate Antigens (Triple-Knockout). Sci Rep (2020) 10(1):9771. 10.1038/s41598-020-66311-3
40.
Yamamoto T Hara H Iwase H Jagdale A Bikhet MH Morsi MA et al The Final Obstacle to Successful Pre‐Clinical Xenotransplantation? Xenotransplantation (2020) 27(5):e12596. 10.1111/xen.12596
41.
Li Q Shaikh S Iwase H Long C Lee W Zhang Z et al Carbohydrate Antigen Expression and Anti‐Pig Antibodies in New World Capuchin Monkeys: Relevance to Studies of Xenotransplantation. Xenotransplantation (2019) 26(3):e12498. 10.1111/xen.12498
42.
French BM Sendil S Sepuru KM Ranek J Burdorf L Harris D et al Interleukin-8 Mediates Neutrophil-Endothelial Interactions in Pig-To-Human Xenogeneic Models. Xenotransplantation (2018) 25(2):e12385. 10.1111/xen.12385
43.
Laird CT Hassanein W O’Neill NA French BM Cheng X Fogler WE et al P- and E-Selectin Receptor Antagonism Prevents Human Leukocyte Adhesion to Activated Porcine Endothelial Monolayers and Attenuates Porcine Endothelial Damage. Xenotransplantation (2018) 25(2):e12381. 10.1111/xen.12381
44.
Gaca JG Lesher A Aksoy O Ruggeri ZM Parker W Davis RD . The Role of the Porcine Von Willebrand Factor: Baboon Platelet Interactions in Pulmonary Xenotransplantation. Transplantation (2002) 74(11):1596–603. 10.1097/00007890-200212150-00018
45.
Kim YT Lee HJ Lee SW Kim JY Wi HC Park SJ et al Pre-Treatment of Porcine Pulmonary Xenograft with Desmopressin: A Novel Strategy to Attenuate Platelet Activation and Systemic Intravascular Coagulation in an ex-vivo Model of swine-to-human Pulmonary Xenotransplantation. Xenotransplantation (2008) 15(1):27–35. 10.1111/j.1399-3089.2008.00445.x
46.
Connolly MR Kuravi K Burdorf L Sorrells L Morrill B Cimeno A et al Humanized Von Willebrand Factor Reduces Platelet Sequestration in Ex Vivo and In Vivo Xenotransplant Models. Xenotransplantation (2021) 28(6):e12712. 10.1111/xen.12712
47.
Roussel JC Moran CJ Salvaris EJ Nandurkar HH D’Apice AJF Cowan PJ . Pig Thrombomodulin Binds Human Thrombin But Is a Poor Cofactor for Activation of Human Protein C and TAFI. Am J Transpl (2008) 8(6):1101–12. 10.1111/j.1600-6143.2008.02210.x
48.
Lawson JH Daniels LJ Platt JL . The Evaluation of Thrombomodulin Activity in Porcine to Human Xenotransplantation. Transpl Proc (1997) 29(1–2):884–5. 10.1016/S0041-1345(96)00192-3
49.
Chen D Riesbeck K McVey JH Kemball-Cook G Tuddenham EG Lechler RI et al Regulated Inhibition of Coagulation by Porcine Endothelial Cells Expressing P-Selectin-Tagged Hirudin and Tissue Factor Pathway Inhibitor Fusion Proteins. Transplantation (1999) 68(6):832–9. 10.1097/00007890-199909270-00016
50.
Kopp CW Siegel JB Hancock WW Anrather J Winkler H Geczy CL et al Effect of Porcine Endothelial Tissue Factor Pathway Inhibitor on Human Coagulation Factors. Transplantation (1997) 63(5):749–58. 10.1097/00007890-199703150-00023
51.
Kopp CW Grey ST Siegel JB McShea A Vetr H Wrighton CJ et al Expression of Human Thrombomodulin Cofactor Activity in Porcine Endothelial Cells. Transplantation (1998) 66(2):244–51. 10.1097/00007890-199807270-00019
52.
Schulte am Esch J Rogiers X Robson SC . Molecular Incompatibilities in Hemostasis Between Swine and Men--Impact on Xenografting. Ann Transpl (2001) 6(3):12–6.
53.
Chaban R Ileka IS Pierson RN III . Lung Xenotransplantation: Current Status 2023. Eur J Transpl (2023) 1(3):217–25. 10.57603/EJT-311
54.
Schroeder C Allan JS Nguyen BN Wu G Zhang T Azimzadeh AM et al Hyperacute Rejection Is Attenuated in Galt Knockout Swine Lungs Perfused Ex Vivo with Human Blood. Transpl Proc (2005) 37(1):512–3. 10.1016/j.transproceed.2004.12.133
55.
Cooper DKC Ekser B Ramsoondar J Phelps C Ayares D . The Role of Genetically Engineered Pigs in Xenotransplantation Research. J Pathol (2016) 238(2):288–99. 10.1002/path.4635
56.
Schroeder C Pfeffer S Wu G Zorn GL Ding L Allen C et al Effect of Complement Fragment 1 Esterase Inhibition on Survival of Human Decay-Accelerating Factor Pig Lungs Perfused with Human Blood. J Heart Lung Transpl (2003) 22(12):1365–75. 10.1016/S1053-2498(03)00026-3
57.
Leventhal J Dalmasso A Cromwell J Platt JL Manivel CJ Bolman RM et al Prolongation of Cardiac Xenograft Survival by Depletion of Complement. Transplantation (1993) 55(4):857–65. 10.1097/00007890-199304000-00033
58.
Blum MG Collins BJ Chang AC Zhang JP Knaus SA Pierson RN III . Complement Inhibition by FUT-175 and K76-COOH in a Pig-To-Human Lung Xenotransplant Model. Xenotransplantation (1998) 5(1):35–43. 10.1111/j.1399-3089.1998.tb00006.x
59.
Azimzadeh AM Kelishadi SS Ezzelarab MB Singh AK Stoddard T Iwase H et al Early Graft Failure of Galtko Pig Organs in Baboons Is Reduced by Expression of a Human Complement Pathway-Regulatory Protein. Xenotransplantation (2015) 22(4):310–6. 10.1111/xen.12176
60.
Harris DG Quinn KJ French BM Schwartz E Kang E Dahi S et al Meta-Analysis of the Independent and Cumulative Effects of Multiple Genetic Modifications on Pig Lung Xenograft Performance During Ex Vivo Perfusion with Human Blood. Xenotransplantation (2015) 22(2):102–11. 10.1111/xen.12149
61.
Martínez-Sanz P Hoogendijk AJ Verkuijlen PJJH Schornagel K van Bruggen R van den Berg TK et al CD47-SIRPα Checkpoint Inhibition Enhances Neutrophil-Mediated Killing of Dinutuximab-Opsonized Neuroblastoma Cells. Cancers (2021) 13(17):4261. 10.3390/cancers13174261
62.
Kaur S Isenberg JS Roberts DD . CD47 (Cluster of Differentiation 47). Atlas Genet Cytogenet Oncol Haematol (2021) 25(2):83–102.
63.
Ide K Wang H Tahara H Liu J Wang X Asahara T et al Role for CD47-SIRPalpha Signaling in Xenograft Rejection by Macrophages. Proc Natl Acad Sci U S A (2007) 104(12):5062–6. 10.1073/pnas.0609661104
64.
Willingham SB Volkmer JP Gentles AJ Sahoo D Dalerba P Mitra SS et al The CD47-Signal Regulatory Protein Alpha (Sirpa) Interaction Is a Therapeutic Target for Human Solid Tumors. Proc Natl Acad Sci U S A (2012) 109(17):6662–7. 10.1073/pnas.1121623109
65.
Watanabe H Ariyoshi Y Pomposelli T Takeuchi K Ekanayake-Alper DK Boyd LK et al Intra‐Bone Bone Marrow Transplantation From hCD47 Transgenic Pigs to Baboons Prolongs Chimerism to >60 Days and Promotes Increased Porcine Lung Transplant Survival. Xenotransplantation (2020) 27(1):e12552. 10.1111/xen.12552
66.
Watanabe H Sahara H Nomura S Tanabe T Ekanayake-Alper DK Boyd LK et al GalT-KO Pig Lungs Are Highly Susceptible to Acute Vascular Rejection in Baboons, Which May Be Mitigated by Transgenic Expression of hCD47 on Porcine Blood Vessels. Xenotransplantation (2018) 25(5):e12391. 10.1111/xen.12391
67.
Tsushima Y Jang JH Yamada Y Schwendener R Suzuki K Weder W et al The Depletion of Donor Macrophages Reduces Ischaemia-Reperfusion Injury After Mouse Lung Transplantation. Eur J Cardiothorac Surg (2014) 45(4):703–9. 10.1093/ejcts/ezt489
68.
Gaca JG Palestrant D Lukes DJ Olausson M Parker W Davis RD . Prevention of Acute Lung Injury in Swine: Depletion of Pulmonary Intravascular Macrophages Using Liposomal Clodronate. J Surg Res (2003) 112(1):19–25. 10.1016/S0022-4804(03)00142-2
69.
Cantu E Gaca JG Palestrant D Baig K Lukes DJ Gibson SE et al Depletion of Pulmonary Intravascular Macrophages Prevents Hyperacute Pulmonary Xenograft Dysfunction. Transplantation (2006) 81(8):1157–64. 10.1097/01.tp.0000169758.57679.2a
70.
Knapp K Zebisch M Pippel J El-Tayeb A Müller CE Sträter N . Crystal Structure of the Human ecto-5’-nucleotidase (CD73): Insights Into the Regulation of Purinergic Signaling. Structure (2012) 20(12):2161–73. 10.1016/j.str.2012.10.001
71.
Antonioli L Pacher P Vizi ES Haskó G . CD39 and CD73 in Immunity and Inflammation. Trends Mol Med (2013) 19(6):355–67. 10.1016/j.molmed.2013.03.005
72.
Puga YG Bongoni AK Pradier A Madelon N Papaserafeim M Sfriso R et al Release of Pig Leukocytes and Reduced Human NK Cell Recruitment During Ex Vivo Perfusion of HLA-E/human CD46 Double-Transgenic Pig Limbs with Human Blood. Xenotransplantation (2018) 25(1):e12357. 10.1111/xen.12357
73.
Khalfoun B Barrat D Watier H Machet MC Arbeille-Brassart B Riess JG et al Development of an Ex Vivo Model of Pig Kidney Perfused With Human Lymphocytes. Analysis of Xenogeneic Cellular Reactions. Surgery (2000) 128(3):447–57. 10.1067/msy.2000.107063
74.
Laird CT Burdorf L French BM Kubicki N Cheng X Braileanu G et al Transgenic Expression of Human Leukocyte antigen-E Attenuates GalKO.hCD46 Porcine Lung Xenograft Injury. Xenotransplantation (2017) 24(2):e12294. 10.1111/xen.12294
75.
Forte P Baumann BC Schneider MKJ Seebach JD . HLA-Cw4 Expression on Porcine Endothelial Cells Reduces Cytotoxicity and Adhesion Mediated by CD158a+ Human NK Cells. Xenotransplantation (2009) 16(1):19–26. 10.1111/j.1399-3089.2009.00510.x
76.
Ezzelarab M Garcia B Azimzadeh A Sun H Lin CC Hara H et al The Innate Immune Response and Activation of Coagulation in α1,3-galactosyltransferase gene-knockout Xenograft Recipients. Transplantation (2009) 87(6):805–12. 10.1097/TP.0b013e318199c34f
77.
Miura S Habibabady ZA Pollok F Ma M Rosales IA Kinoshita K et al TNX-1500, a Crystallizable Fragment–Modified Anti-CD154 Antibody, Prolongs Nonhuman Primate Cardiac Allograft Survival. Am J Transpl (2023) 23(8):1182–93. 10.1016/j.ajt.2023.03.025
78.
Zhang T Azimzadeh AM Sun W O'Neill NA Sievert E Bergbower E et al Selective CD28 Inhibition Modulates Alloimmunity and Cardiac Allograft Vasculopathy in Anti–CD154-treated Monkeys. Transplantation (2018) 102(3):e90–100. 10.1097/TP.0000000000002044
79.
Lassiter G Otsuka R Hirose T Rosales I Karadagi A Tomosugi T et al TNX-1500, a Crystallizable Fragment–Modified Anti-CD154 Antibody, Prolongs Nonhuman Primate Renal Allograft Survival. Am J Transpl (2023) 23(8):1171–81. 10.1016/j.ajt.2023.03.022
80.
Mohiuddin MM Singh AK Corcoran PC Thomas Iii ML Clark T Lewis BG et al Chimeric 2C10R4 Anti-CD40 Antibody Therapy Is Critical for Long-Term Survival of GTKO.hCD46.hTBM pig-to-primate Cardiac Xenograft. Nat Commun (2016) 7(1):11138. 10.1038/ncomms11138
81.
Wu G Pfeiffer S Schröder C Zhang T Nguyen BN Lea W et al Co-stimulation Blockade Targeting CD154 and CD28/B7 Modulates the Induced Antibody Response After a Pig-To-Baboon Cardiac Xenograft. Xenotransplantation (2005) 12(3):197–208. 10.1111/j.1399-3089.2005.00221.x
Summary
Keywords
xenotransplantation, lung, pig-to-baboon xenotransplantation, non-human primate model, decedent model
Citation
Takemoto S, Burdorf L and Pierson RN (2026) Pig Lung Xenotransplantation: Barriers on the Road to Clinical Translation. Transpl. Int. 38:15542. doi: 10.3389/ti.2025.15542
Received
05 September 2025
Revised
22 November 2025
Accepted
23 December 2025
Published
09 January 2026
Volume
38 - 2026
Updates
Copyright
© 2026 Takemoto, Burdorf and Pierson.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Lars Burdorf, lburdorf@mgh.harvard.edu
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.